文献速递流行病学与生物统计真实世界研究与卫生经济

围产期感染HIV青少年的流行病学:跨区域全球队列分析

The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis.
PubMed 文献 · PLoS Med · 2018-03-01

该研究 pooled 12个队列网络共38,187名围产期感染HIV青少年(APHs)的回顾性纵向数据,描述其地理与时间特征及死亡率结局。15岁时累积死亡率为2.6%(95%CI 2.4%-2.8%),欧洲最低(0.8%),南美与加勒比最高(4.4%);撒哈拉以南非洲失访率最高(13.2%)。

要点

  • 15岁时APHs累积死亡率为2.6%,欧洲最低0.8%,南美与加勒比最高4.4%。
  • 撒哈拉以南非洲失访率最高达13.2%,可能影响区域间死亡率比较。
  • 首次就诊和启动ART的中位年龄区域差异大,北美最早,撒哈拉以南非洲最晚。

核心结论

  • 尽管死亡率可能被低估,撒哈拉以南非洲、南亚与东南亚及南美与加勒比的APHs死亡率仍显著高于欧洲。

研究设计与样本

  • 通过CIPHER协作 pooled 12个队列网络的回顾性纵向个体数据,纳入10岁前入组、非水平感染且随访超过10岁的HIV感染儿童。
  • 共纳入来自51个国家的38,187名APHs,其中51%为女性,79%来自撒哈拉以南非洲,65%居住于低收入国家。

主要发现

  • 总队列青少年随访中位时长为3.1年(IQR 1.5-5.2),欧洲为6.4年(IQR 3.6-8.0),撒哈拉以南非洲为2.1年(IQR 0.9-3.8)。
  • 首次就诊中位年龄从北美0.7岁(IQR 0.3-2.1)到撒哈拉以南非洲7.1岁(IQR 5.3-8.6)不等。
  • ART启动中位年龄从北美0.9岁(IQR 0.4-2.6)到撒哈拉以南非洲7.9岁(IQR 6.0-9.3)不等。
  • 15岁时累积死亡率、转出率和失访率分别为2.6%(95%CI 2.4%-2.8%)、15.6%(95%CI 15.1%-16.0%)和11.3%(95%CI 10.9%-11.8%)。
  • 死亡率欧洲最低为0.8%(95%CI 0.5%-1.1%),南美与加勒比最高为4.4%(95%CI 3.1%-6.1%);失访率南美与加勒比最低为4.8%(95%CI 3.4%-6.7%),撒哈拉以南非洲最高为13.2%(95%CI 12.6%-13.7%)。

临床怎么用

  • 应针对撒哈拉以南非洲、南亚与东南亚及南美与加勒比等死亡率较高区域加强APHs的随访与照护。
  • 需关注撒哈拉以南非洲高失访率对结局评估的影响,并改进保留策略。

局限性

  • 撒哈拉以南非洲高失访率可能影响区域间死亡率比较。
  • 部分国家仅纳入接受ART的APHs数据。
  • 缺乏尼日利亚等高负担国家的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Globally, the population of adolescents living with perinatally acquired HIV (APHs) continues to expand. In this study, we pooled data from observational pediatric HIV cohorts and cohort networks, allowing comparisons of adolescents with perinatally acquired HIV in "real-life" settings across multiple regions. We describe the geographic and temporal characteristics and mortality outcomes of APHs across multiple regions, including South America and the Caribbean, North America, Europe, sub-Saharan Africa, and South and Southeast Asia. METHODS AND FINDINGS: Through the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), individual retrospective longitudinal data from 12 cohort networks were pooled. All children infected with HIV who entered care before age 10 years, were not known to have horizontally acquired HIV, and were followed up beyond age 10 years were included in this analysis conducted from May 2016 to January 2017. Our primary analysis describes patient and treatment characteristics of APHs at key time points, including first HIV-associated clinic visit, antiretroviral therapy (ART) start, age 10 years, and last visit, and compares these characteristics by geographic region, country income group (CIG), and birth period. Our secondary analysis describes mortality, transfer out, and lost to follow-up (LTFU) as outcomes at age 15 years, using competing risk analysis. Among the 38,187 APHs included, 51% were female, 79% were from sub-Saharan Africa and 65% lived in low-income countries. APHs from 51 countries were included (Europe: 14 countries and 3,054 APHs; North America: 1 country and 1,032 APHs; South America and the Caribbean: 4 countries and 903 APHs; South and Southeast Asia: 7 countries and 2,902 APHs; sub-Saharan Africa, 25 countries and 30,296 APHs). Observation started as early as 1982 in Europe and 1996 in sub-Saharan Africa, and continued until at least 2014 in all regions. The median (interquartile range [IQR]) duration of adolescent follow-up was 3.1 (1.5-5.2) years for the total cohort and 6.4 (3.6-8.0) years in Europe, 3.7 (2.0-5.4) years in North America, 2.5 (1.2-4.4) years in South and Southeast Asia, 5.0 (2.7-7.5) years in South America and the Caribbean, and 2.1 (0.9-3.8) years in sub-Saharan Africa. Median (IQR) age at first visit differed substantially by region, ranging from 0.7 (0.3-2.1) years in North America to 7.1 (5.3-8.6) years in sub-Saharan Africa. The median age at ART start varied from 0.9 (0.4-2.6) years in North America to 7.9 (6.0-9.3) years in sub-Saharan Africa. The cumulative incidence estimates (95% confidence interval [CI]) at age 15 years for mortality, transfers out, and LTFU for all APHs were 2.6% (2.4%-2.8%), 15.6% (15.1%-16.0%), and 11.3% (10.9%-11.8%), respectively. Mortality was lowest in Europe (0.8% [0.5%-1.1%]) and highest in South America and the Caribbean (4.4% [3.1%-6.1%]). However, LTFU was lowest in South America and the Caribbean (4.8% [3.4%-6.7%]) and highest in sub-Saharan Africa (13.2% [12.6%-13.7%]). Study limitations include the high LTFU rate in sub-Saharan Africa, which could have affected the comparison of mortality across regions; inclusion of data only for APHs receiving ART from some countries; and unavailability of data from high-burden countries such as Nigeria. CONCLUSION: To our knowledge, our study represents the largest multiregional epidemiological analysis of APHs. Despite probable under-ascertained mortality, mortality in APHs remains substantially higher in sub-Saharan Africa, South and Southeast Asia, and South America and the Caribbean than in Europe. Collaborations such as CIPHER enable us to monitor current global temporal trends in outcomes over time to inform appropriate policy responses.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Slogrove AL, Schomaker M, Davies MA, et al. The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Med. 2018. PMID: 29494593. doi:10.1371/journal.pmed.1002514

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。